Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanogam 100 mg/ml pharmacokinetics and safety study
NL-OMON38799Phase 3Active, not recruiting
- Sponsor
- Sanquin
- Start
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Nanogam in primary hypogammaglobulinemia and Primary antibody deficiency (PAD), sponsored by Sanquin. Primary endpoint: Pharmacokinetic comparison of Nanogam 100 mg/ml versus Nanogam 50 mg/ml. Started Jan 2014; status: active, not recruiting.
02
Drugs
Nanogam
03
Conditions
primary hypogammaglobulinemiaPrimary antibody deficiency (PAD)
Beyond the preview
Go deeper on NL-OMON38799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38799.